One hundred and sixty-nine patients between the ages of Retrobulbar injections were performed with a 23 gauge, 30 mm long disposable needle. The needle was intro duced at the junction of the lateral one-third with the medial two-thirds of the inferior orbital margin. Up to 5 m1 of 0.5% bupivacaine hydrochloride with 1500 units of hyaluronidase were used to achieve effective akinesia.
Eye (1994) 8, 465-466 © 1994 Royal College of Ophthalmologists 52 and 97 years were recruited for the study. Informed, written consent was obtained from all patients. Approval for the study was given by the hospital ethics committee.
The study was a placebo-controlled, double-masked comparison of EMLA with amethocaine cream and placbo. The treatments were distributed at random and at the end of the study 58 patients had received EMLA, 56 placebo and 55 amethocaine. None of the patients received any premedication either orally or intravenously.
EMLA 5% cream consists of a mixture of lignocaine base 25 mg/ml and prilocaine base 25 mg/ml. Ametho caine I % cream consists of the drug in a non-greasy base. 
RESULTS
The results from 169 patients undergoing cataract surgery were analysed. No patient was withdrawn from the study.
The characteristics of the three groups of patients are pre sented in Table 1 . There were no statistical differences between the three groups in their baseline characteristics.
The patients' responses to the puncture of the skin during retrobulbar injection as observed by the doctor giving the injection are shown in Table II . Treatment with EMLA cream (X " = 10.6, df = 2,p<O.OI) and with ame thocaine cream (X " = 9.5, df = 2, p<O.Ol) resulted in sig nificantly less pain when compared with placebo.
However, there was no statistically significant difference between EMLA and amethocaine (X " = 2.2, df = 2, p>O.l).
The pain at the time of skin puncture during retrobulbar injection as subjectively assessed by the patients is indi cated in Table III 
4).
No significant local adverse effects were noted and there were no cases of marked erythema, scaling, oedema, or allergic reaction in either the EMLA, amethocaine or placebo groups.
DISCUSSION
Our study suggests that amethocaine cream is equally effective as EMLA in alleviating the pain associated with needle puncture of the skin during retrobulbar injection.
Although the safety of topically applied amethocaine cream has been questioned after several reports of toxic reactions,+-6 it has been pointed out that when ametho caine cream is applied to the skin, as opposed to mucous membranes, both the speed and degree of systemic absorption are greatly reduced.7 In addition no local or systemic side-effects were encountered in this study. In conclusion, we believe that amethocaine cream is as effec tive and safe as EMLA in reducing the pain of the skin puncture during retrobulbar injection.
